Development of Chimeric Hepatitis B (HBV) – Norovirus (NoV) P particle as candidate vaccine against Hepatitis B and norovirus infection

Simple item page
dc.contributor.authorGiri-Rachman, Ernawati Arifinen
dc.contributor.authorIrasonia Tan, Marselinaen
dc.contributor.authorRamesh, Ashwinen
dc.contributor.authorFajar, Putri Ayuen
dc.contributor.authorNurul Ilmi, Annisaen
dc.contributor.authorRetnoningrum, Debbie Sofieen
dc.contributor.authorHertadi, Rukmanen
dc.contributor.authorIrawan, Aprilianien
dc.contributor.authorWojciechowska, Gladys Emmanuella Putrien
dc.contributor.authorYuan, Lijuanen
dc.date.accessioned2023-10-23T13:49:41Zen
dc.date.available2023-10-23T13:49:41Zen
dc.date.issued2023-08-01en
dc.date.updated2023-10-21T03:02:08Zen
dc.description.abstractIntroduction: Hepatitis B remains a global problem with no effective treatment. Here, a mucosal vaccine candidate was developed with HBsAg and HBcAg, to provide both prophylactic and therapeutic protection against hepatitis B. The antigens were presented using the P particle of human norovirus (HuNov). As a result, the chimeric HBV – HuNoV P particle can act as a dual vaccine for hepatitis B and HuNoV. Methods: The vaccine candidate was expressed and purified from Escherichia coli BL21 (DE3) cells. HBV-HuNoV chimeric P particles were successfully expressed and isolated, with sizes of approximately 25.64 nm. Then, the HBV-HuNoV chimeric P particles were evaluated for safety and immunogenicity in mice and gnotobiotic (Gn) pigs. After three doses (5 µg/dose in mice and 200 µg/dose in Gn pigs) of intranasal immunization, humoral and cellular immune responses, as well as toxicity, were evaluated. Results: The vaccine candidate induced strong HBV-HuNoV specific IFN-γ producing T-cell responses in the ileum, spleen, and blood of Gn pigs. Serum IgG and IgA antibodies against HBV-HuNoV chimeric P particles also increased significantly in Gn pigs. Increased HBsAg- and HuNoV-specific serum IgG responses were observed in mice and Gn pigs, although not statistically significant. The vaccine candidate did not show any toxicity in mice. Conclusions: In summary, the chimeric HBV-HuNoV P particle vaccine given intranasally was safe and induced strong cellular and humoral immune responses in Gn pig. Modifications to the vaccine structure and dosage need to be evaluated in future studies to further enhance immunogenicity and induce more balanced humoral and cellular responses.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier100354 (Article number)en
dc.identifier.doihttps://doi.org/10.1016/j.jvacx.2023.100354en
dc.identifier.eissn2590-1362en
dc.identifier.issn2590-1362en
dc.identifier.orcidYuan, Lijuan [0000-0003-0709-5228]en
dc.identifier.otherPMC10372314en
dc.identifier.otherS2590-1362(23)00095-5 (PII)en
dc.identifier.pmid37519778en
dc.identifier.urihttp://hdl.handle.net/10919/116526en
dc.identifier.volume14en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pubmed/37519778en
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectDual vaccineen
dc.subjectHepatitis B virusen
dc.subjectImmunological responseen
dc.subjectIntranasal vaccinationen
dc.subjectNorovirusen
dc.subject3207 Medical Microbiologyen
dc.subject32 Biomedical and Clinical Sciencesen
dc.subject3204 Immunologyen
dc.subjectInfectious Diseasesen
dc.subjectLiver Diseaseen
dc.subjectBiodefenseen
dc.subjectImmunizationen
dc.subjectBiotechnologyen
dc.subjectHepatitis - Ben
dc.subjectFoodborne Illnessen
dc.subjectDigestive Diseasesen
dc.subjectPreventionen
dc.subjectHepatitisen
dc.subjectEmerging Infectious Diseasesen
dc.subjectVaccine Relateden
dc.subject3 Prevention of disease and conditions, and promotion of well-beingen
dc.subject3.4 Vaccinesen
dc.subject3 Good Health and Well Beingen
dc.titleDevelopment of Chimeric Hepatitis B (HBV) – Norovirus (NoV) P particle as candidate vaccine against Hepatitis B and norovirus infectionen
dc.title.serialVaccine: Xen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherJournal Articleen
dcterms.dateAccepted2023-07-10en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Biomedical Sciences and Pathobiologyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Development of Chimeric Hepatitis B.pdf
Size:
9.96 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Scholarly Works, Biomedical Sciences and Pathobiology